Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study).

Cancer Gene Ther · 2025 · PMC12535911 · PMID 40715484

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0520

boldest claim

The sentences

showed a trendp = 0.052so close (0.05 < p ≤ 0.1)

In PSM-adjusted analysis, DG showed a trend towards longer DFS ( p = 0.052) and significantly improved OS ( p = 0.016).

also in 53,322 other papers

marginally statistically significantp = 0.052so close (0.05 < p ≤ 0.1)

In the PSM-adjusted cohort, a trend toward longer DFS was observed in DG arm compared to the OXA arm, though the difference was only marginally statistically significant (mDFS 133.2 vs. 61.4 months; hazard ratio [HR] 1.56; 95% CI 0.99–2.46; p = 0.052) as shown in Fig. 2a .

also in 1,110 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.